RITCH Suspension

In patients with a known hypersensitivity to Fexofenadine or any of its ingredients.

The most common side effects are headache, fatigue, dizziness or drowsiness and nausea. In rare cases, rash, urticaria, pruritus and hypersensitivity reactions such as angioedema, dyspnoea, chest tightness, flushing and systemic anaphylaxis have been reported.

Plasma concentrations of Fexofenadine have been increased when given with Erythromycin or Ketoconazole. Fexofenadine had no effect on the pharmacokinetics of Erythromycin or Ketoconazole. Antacid containing Aluminium and Magnesium Hydroxide reduces the absorption of Fexofenadine. It is advisable to leave 2 hours between administration or Fexofenadine and Alminium and Magnesium Hydroxide containing Antacids.

Pregnancy category B2

There are no adequate and well controlled studies in pregnant women exposed to Fexofenadine alone or through the administration of Terfenadine. Fexofenadine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Fexofenadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fexofenadine is administered to a nursing woman.

Studies in the elderly, patients with hepatic impairment and patients with cardiac disease exposed to Fexofenadine through administration of Terfenadine showed no statistically significant differences in pharmacokinetic parameters for Fexofenadine when compares to those pharmacokinetic parameters in healthy individuals. There is only limited data in the elderly and renally or hepatically impaired patients. Fexofenadine should be administered with care in these special groups. Fexofenadine causes drowsiness less than other antihistamines; therefore caution should be advised during drive or operate potentially dangerous machinery

Fexofenadine is an orally active non-sedating H1 receptor antagonist and is effective for the relief of symptoms associated with allergic rhinitis and urticaria. Fexofenadine does not appear to cross the blood brain barrier.